CTLA4 and rheumatoid arthritis: In rheumatoid arthritis, co-treatment with anti-TNFα and anti-IL1 mAbs and the combination of anti-TNFα mAb and abatacept (CTLA4-Fc/T-cell activation inhibitor) have been evaluated.